Woodline Partners LP Akero Therapeutics, Inc. Transaction History
Woodline Partners LP
- $17.6 Billion
- Q2 2025
A detailed history of Woodline Partners LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 2,467,350 shares of AKRO stock, worth $119 Million. This represents 0.75% of its overall portfolio holdings.
Number of Shares
2,467,350
Previous 480,736
413.24%
Holding current value
$119 Million
Previous $19.5 Million
576.55%
% of portfolio
0.75%
Previous 0.14%
Shares
6 transactions
Others Institutions Holding AKRO
# of Institutions
296Shares Held
92.2MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$324 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$275 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$268 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$263 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$218 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.23B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...